Human Thyroid Carcinoma RET Gene Fusions Detection Kit
Real Time PCR
CE-IVD Certificate no.：No.MDD-SZ-XWA1-180523
Only for scientific research use in China
Gene Mutation and Thyroid Carcinoma
Thyroid carcinoma is one of the most common malignant thyroid neoplasms, in which about 5%-40% of the patients with papillary thyroid carcinoma (PTC) are RET fusion carriers. RET gene fusion is related to ionizing radiation. Thyroid carcinoma caused by environmental exposure to ionizing radiation are thought to be associated with RET gene fusion. When RET gene fusion occurs, it is not necessary for ligand engagement to induce RET dimerization, the mutated fusion protein will activate kinase domain of itself and downstream signaling of RAS/ERK, PI3K/AKT and MAPK/JNK pathways permanently, thus leads to cancer finally.
Detected Genes and Sites
|Product Name||Technology||Product Specification||Matched Instrument||Sample Type|
Applicable People and Detected Significance
• Patients with papillary thyroid carcinoma.
• This kit is intended for the qualitative detection of RET gene fusions. The results can be used to guide the selection of RET kinase inhibitor treatment and assist the clinician to select suitable target drugs for patients with papillary thyroid carcinoma, such as Vandertani.
Accuracy and Reliability: Detection with closed tubes. Prevent contamination.
High Sensitivity: Accurate detection of trace amount of mutated RNA .
Easy operation: Systematized prosess. Easy to operation.